Microneedling with topical autologous Platelet rich plasma versus intralesional Triamcinolone acetonide in Alopecia Areata

Phase 4

Not yet recruiting

Conditions: Other alopecia areata,

Registration Number: CTRI/2021/03/031963

Lead Sponsor: Dr Surabhi Dayal

Brief Summary: 40 patients of clinically diagnosed Alopecia Areata of the scalp less than or equal to 5 patches and less than or equal to 25 % scalp involvement and who have not taken any treatment for hair loss in the past 3 months and are willing to consent for enrollment in the study will be randomly divided into 2 groups of 20 each using a computer generated randomization chart.

**Group -1 (****COMBINATION OF MICRONEEDLING WITH TOPICAL AUTOLOGOUS PLATELET RICH PLASMA GROUP****)**: Patients in this group will be treated by microneedling technique using dermaroller in combination with topical autologous platelet rich plasma at every 4 weeks interval for a total period of 16 weeks.

**Group- 2 (****INTRALESIONAL TRIAMCINOLONE ACETONIDE GROUP****):** Patients in this group will be treated with intralesional Injection of Triamcinolone acetonide 10 mg/ml at every 4 weeks interval for a period of 16 weeks.

Results of both the treatments of group 1 and group 2 will be compared at the end of therapy on the basis of reduction in the mean SALT scores from the baseline and Visual Analogue Scale.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

Clinically diagnosed as Alopecia Areata of the scalp less than or equal to 5 patches and less than or equal to 25 % scalp involvement and who have not taken any treatment for hair loss in the past 3 months and are willing to consent for enrollment in the study.

Exclusion Criteria

Patients with history of bleeding disorders,on anticoagulant medications,with an active infection at local site,having keloidal tendency, having psoriasis or lichen planus because of risk of Koebner phenomenon or any other dermatological disease,having alopecia totalis or alopecia universalis,who had taken any treatment for hair-loss in the past 3 months,with history of hypersensitivity to formulation used in the study,Severe systemic illness or malignancy,Pregnant and lactating mothers.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Decrease in the mean SALT (Severity of Alopecia Areata Tool)scores from the baseline will be compared between the two groups.	Baseline,4 weeks,8 weeks,12 weeks and 16 weeks.

Secondary Outcome Measures

Name	Time	Method
VISUAL ANALOGUE SCALE: Patients	to grade their improvement from 0 to 10 on a 10 point scale as per his/her satisfaction.

Trial Locations

Locations (1): Pt B.D. Sharma, PGIMS, Rohtak
🇮🇳
Rohtak, HARYANA, India
Pt B.D. Sharma, PGIMS, Rohtak
🇮🇳Rohtak, HARYANA, India
Dr Surabhi Dayal
Principal investigator
9896205319
surabhidayal7@gmail.com